Vision
Through world-class research, to bring hope to those touched by cancer.

Mission
To advance the understanding and treatment of cancer by making an internationally recognised contribution to cancer research which is accessible to the community.

As a non-government funded organisation, the Institute relies on the community’s support to maintain and build the research program. This is done through wonderful donations of money and time.

Our values at the Fiona Elsey Cancer Research Institute are:
• Excellence in research
• Connection to the community
• Integrity, ethical behaviour, transparency and accessibility.
Because of the generosity of our donor community, we have been able to develop an internationally recognised research program in Ballarat.

We thank you for your continued support.
Our research team is working hard to unlock the riddles of cancer. We are well positioned to do this, with a world class facility and team based at the Ballarat Technology Park.
### Contents

- message from our Chair .......................................................... 4
- message from our Honorary Director ...................................... 5
- a young girl’s dream ................................................................. 6
- our research ............................................................................. 7
- senior research staff ................................................................. 8
- collaborative partnerships and networks ................................. 9
- research team ......................................................................... 10
- publications ............................................................................ 12
- governance .............................................................................. 13
- scientific advisory committee .................................................. 13
- financial commentary .............................................................. 15
- donor contribution ................................................................... 16
- fundraisers and events ............................................................. 21
Message from Our Chair

The Institute celebrates its 20th year in 2018. We are now a clearly well-regarded Institute whose scientific research is now beginning to bear fruit. It has been a wonderful journey.

Led by our Institute Director, Professor George Kannourakis, the Institute is making a world-class contribution to cancer research, with recent recognition of achievements in immunotherapy targets for ovarian cancer and histiocytic disorders, along with significant new findings in immune studies of leukaemia. Our research is primarily focused on enabling the immune system to fight cancer.
The last few years have seen the expansion of the Institute’s research effort. With an increase in scientific staff and students, and a strong focus on a governance structure whose primary aim to ensure that the Institute’s major goal to carry out high quality research is achieved.
The membership of the Institute’s Board of Management is drawn from community leaders who bring wide-ranging expertise in governance, finance, science and human resources. The purpose of the Board is to ensure the proper governance and sustainability of the Institute. This provides our community of donors and volunteers with the confidence that their most generous support is managed responsibly and put to best use.

It is noteworthy that the Institute is wholly dependent on funds donated through the remarkable generosity of the Institute’s community of donors. It is from their ongoing support that this most critical research into cancer can continue.

Our team, from the researchers, administration, fundraising and communications, are focused and dedicated to our mission of advancing cancer research.
The future of the Institute, as one of the few truly regional cancer research institutes, is both bright and enduring.
On behalf of the Board and team at the Fiona Elsey Cancer Research Institute, I thank you for your support.

Emeritus Professor Wayne Robinson
BVSc, MVsc, PhD, MACVSc, DACVP, DVSc (Hon causa)
Chair, Board of Management

The survival rate for many types of cancer has increased by 20% in the last three decades due to treatment improvements and new interventions brought about by research.*

* Source: Cancer in Australia 2017 report, Australian Institute of Health and Welfare
The last twelve months have been productive in the Institute, with great developments in our key research projects. This has resulted in presentations from our scientific staff at national and international meetings and multiple new scientific publications.

Continual research
Our research team continues to learn how the immune system can fight cancer, with this approach becoming the future treatment alternative to chemotherapy and radiotherapy. Our key projects are in Immunology, Ovarian Cancer, Chronic Lymphocytic Leukaemia and Langerhans Cell Histioctysis. The Institute currently has 9 PhD students from Federation University and 10 senior scientific staff.

Dorevitch Pathology have continued their support for Professor Stuart Berzins’ position, funded in partnership by the Institute and Federation University. Professor Stuart Berzins continues to expand his research into immune cells. He is an internationally recognised expert in NKT and MAIT cells and his team is actively studying haematological and solid malignancies.

In May, we announced the establishment of the John Turner Cancer Research Fund at the Fiona Elsey Cancer Research Institute to make an immediate significant difference and growth to the research program. This followed a significant 1-million-dollar donation by businessman and philanthropist, John Turner. The funds have allowed for an expansion to the research program at the Institute, including additional researchers and equipment. Significant gifts, such as this allow for great leaps in our quest for a cure for cancer.

This fund has also seen the creation of the inaugural John Turner Professorial Cancer Research Fellowship. Professor Nuzhat Ahmed will be the first recipient of this fellowship. Professor Ahmed is an internationally recognised cancer researcher in ovarian cancer and is undertaking ground-breaking research into the Immunology of ovarian cancer.

The immune system is the first line of defence against any disease. Professor Ahmed’s research is focused in area of ovarian cancer, to understand how and why the immune system of ovarian cancer patients is not able to eradicate the cancer. Currently her research is focused on the differences between responsive and non-responsive ovarian cancer protein cells which could lead to the development of new immune based therapies for treating cancer.

Further, the John Turner Cancer Research Fund will allow the purchase of laboratory equipment and the appointment of post-doctoral fellow Dr Dily Leung and PhD scholarships students. This is instrumental to increasing the volume and speed of our projects and the establishment of the Visiting John Turner Professorship for international scientists.

Invaluable community connection
The Institute continues to strive to maintain and develop a strong connection with the community. As a community funded research Institute, this is vital to our longevity. Our doors are open to all interested members of the community to tour the facility. Many supporters and organisations continue to attend events and host functions in our name. These events raise much needed funds, whilst also raising awareness. Our largest community engagement event is the Annual Ballarat Cycle Classic event in February. This event continues to be successful and grow, having celebrated its tenth year in 2017. This event is supported by over 150 registered volunteers.

We are an affiliated Institute of Federation University. Our facility hosts the study of 9 Federation University PhD students, who are supervised and mentored by our senior staff. This is supported by the University providing funding of the PhD student program, providing approximately $65,000.00 per year to the Institute. Additionally, we host budding scientists of the future through our work experience program. These students are typically in year 10 and we welcome the active involvement of many secondary schools in the district.

The research output of the Institute continues to increase and gain recognition with 10 peer-reviewed publications accepted in the last 12 months in high profile journals. The publication of our research cements the relevancy and importance of our work here in Ballarat.

The Institute continues to be well placed to undertake leading cutting-edge research in the role of immune cell in cancer treatment development.

Message from our Honorary Director

Continual research
Our research team continues to learn how the immune system can fight cancer, with this approach becoming the future treatment alternative to chemotherapy and radiotherapy.

Our key projects are in Immunology, Ovarian Cancer, Chronic Lymphocytic Leukaemia and Langerhans Cell Histioctysis. The Institute currently has 9 PhD students from Federation University and 10 senior scientific staff.

Dorevitch Pathology have continued their support for Professor Stuart Berzins’ position, funded in partnership by the Institute and Federation University. Professor Stuart Berzins continues to expand his research into immune cells. He is an internationally recognised expert in NKT and MAIT cells and his team is actively studying haematological and solid malignancies.

In May, we announced the establishment of the John Turner Cancer Research Fund at the Fiona Elsey Cancer Research Institute to make an immediate significant difference and growth to the research program. This followed a significant 1-million-dollar donation by businessman and philanthropist, John Turner. The funds have allowed for an expansion to the research program at the Institute, including additional researchers and equipment. Significant gifts, such as this allow for great leaps in our quest for a cure for cancer.

This fund has also seen the creation of the inaugural John Turner Professorial Cancer Research Fellowship. Professor Nuzhat Ahmed will be the first recipient of this fellowship. Professor Ahmed is an internationally recognised cancer researcher in ovarian cancer and is undertaking ground-breaking research into the Immunology of ovarian cancer.

The immune system is the first line of defence against any disease. Professor Ahmed’s research is focused in area of ovarian cancer, to understand how and why the immune system of ovarian cancer patients is not able to eradicate the cancer. Currently her research is focused on the differences between responsive and non-responsive ovarian cancer protein cells which could lead to the development of new immune based therapies for treating cancer.

Further, the John Turner Cancer Research Fund will allow the purchase of laboratory equipment and the appointment of post-doctoral fellow Dr Dily Leung and PhD scholarships students. This is instrumental to increasing the volume and speed of our projects and the establishment of the Visiting John Turner Professorship for international scientists.

Invaluable community connection
The Institute continues to strive to maintain and develop a strong connection with the community. As a community funded research Institute, this is vital to our longevity. Our doors are open to all interested members of the community to tour the facility. Many supporters and organisations continue to attend events and host functions in our name. These events raise much needed funds, whilst also raising awareness. Our largest community engagement event is the Annual Ballarat Cycle Classic event in February. This event continues to be successful and grow, having celebrated its tenth year in 2017. This event is supported by over 150 registered volunteers.

We are an affiliated Institute of Federation University. Our facility hosts the study of 9 Federation University PhD students, who are supervised and mentored by our senior staff. This is supported by the University providing funding of the PhD student program, providing approximately $65,000.00 per year to the Institute. Additionally, we host budding scientists of the future through our work experience program. These students are typically in year 10 and we welcome the active involvement of many secondary schools in the district.

The research output of the Institute continues to increase and gain recognition with 10 peer-reviewed publications accepted in the last 12 months in high profile journals. The publication of our research cements the relevancy and importance of our work here in Ballarat.

The Institute continues to be well placed to undertake leading cutting-edge research in the role of immune cell in cancer treatment development.

Message from our Honorary Director

Professor George Kannourakis
MBBS, B(Med)Sci, PhD, FRACP
Honorary Director
Fiona grew up in Ballarat in regional Victoria and attended Ballarat High School. In 1990 she was diagnosed with Ewing’s sarcoma at the age of 13. She underwent treatment at the Royal Children’s Hospital, where she was treated by Ballarat paediatric oncologist and haematologist Dr George Kannourakis. Ewing’s Sarcoma at this time had a survival rate of 5% and despite treatment Fiona’s disease progressed.

The relationship between doctor and patient is particularly close and especially when the patient is dying. George Kannourakis was pivotal in enabling Fiona to remain at home in her final weeks. During this time, Fiona asked George why cancer research only occurred in capital cities. She made him promise that he would to make her dream of a regional research centre a reality and work so that other people would not have to go through what she was going through - insightful and brave from a young girl battling a terminal disease.

Speaking about the death of a young child is particularly difficult. It represents every parent’s worst nightmare and every doctors’ most challenging situation. But in 1991, the statistics around Fiona’s illness meant that the likelihood of surviving this illness was remote. What a doctor needs to do is continue trying to outwit the disease, remaining hopeful, but also being practical. Fiona needed care, particularly during the final stages of her illness and George Kannourakis provided that care.

Fiona lost her fight for life in 1991, aged 14, but she inspired all those around her, including her local community. The community rallied to then raise the initial funds to support the establishment of what was known as the Ballarat Cancer Research Centre. In 1998, the Fiona Elsey Cancer Research Laboratory, named in Fiona’s memory, was officially opened.

Each day 367 Australians will be diagnosed with cancer. Families and friends are shattered by the way a challenging illness affects their loved ones and each day people continue to die.
Our research

The 4 key projects being undertaken at the Institute are:

1. **Ovarian cancer**
   Every 11 hours one woman dies of ovarian cancer in Australia. Approximately 1400 Australian women are diagnosed with the cancer each year, and nearly 800 die annually, making ovarian cancer the fourth most common cause of cancer-related death in women in Australia. The high mortality rate in ovarian cancer patients results from the diagnosis of the disease at an advanced-stage. Devastatingly, the five-year survival rate of ovarian patients has remained unchanged and as low as 40% for the last thirty years.

   Professor Nuzhat Ahmed is studying how ovarian cancer patients become resistant to chemotherapy and is working to identify novel molecules which can be used in combination with chemotherapy to eradicate the resistant disease. This is being done by studying the protein profiles of tumour samples from patients before and after chemotherapy treatment. By identifying the proteins involved in chemo-resistance, we hope to develop therapies that will specifically target the pathway involved with chemoresistance.

2. **Immunology**
   This research is focused on empowering the immune system to fight disease. Studies on the immunology of cancer and the role of T cell subsets, NK cells, MAIT (mucosal associated invariant T) cells and gamma-delta T cells in various cancers will continue and expand under the leadership of Professor Stuart Berzins. It is hypothesized that defects in the immune system may predispose to cancer, or allow it to progress, and that treatments that enhance immunity may provide improved treatments against cancer. Our study has identified significant abnormalities in immune cells in various cancers, which may lead to new approaches in treatment in the future.

3. **Chronic lymphoid leukemia (CLL)**
   CLL is the most common type of leukemia in adults in the Western world. There is evidence that genetic components contribute to the aetiology of CLL, but no definitive susceptibility genes have been identified.

   This project is studying the role of immune cells in the regulation of disease progression. The Institute is in a unique position to study over one hundred patients with sequential blood samples. Preliminary data has demonstrated interesting results in the analysis of immune cells in these patients. This work has the potential of identifying new immune checkpoints that may lead to future immune treatments for leukaemias and other cancers.

4. **Histiocytic Diseases**
   A major field of our research is directed towards understanding the basic biology of histiocytic diseases. We have been studying a human form of histiocytosis called Langerhans cell histiocytosis (LCH) for many years. In this disease, cells called Langerhans cells accumulate in various tissues to form cancer-like lesions. The causes and mechanisms controlling the development of LCH are presently unknown.

   In October, we welcomed long term collaboration project partner, Professor Jan Inge Henter from the Karolinska Institute in Stockholm, Sweden. The visit was a wonderful opportunity to promote the Institute’s ground-breaking research into rare cancer, Langerhans Cell Histiocytosis (LCH). This Visiting Professorship was funded as part of the recently established John Turner Cancer Research Fund and is a beneficial relationship and connection for the Institute.

In 2018 new research projects will commence at the Institute in the field of kidney, bladder, gall bladder and liver cancers. We look forward to sharing further details about these projects with the community in the near future.

Most people in Australia will be touched by cancer at some stage in their lives either personally or through family and friends.
Senior research staff

Professor George Kannourakis
MB, BS, BDipSci, PhD, FRACP - Honorary Director, Fiona Elsey Cancer Research Institute
George oversees all research and administration at the Institute. He has a wealth of experience in cancer cell biology, having obtained his PhD from The University of Melbourne for his research at the Walter and Eliza Hall Institute of Medical Research. George is Adjunct Professor of Cancer Biology at Federation University and has been a practising oncologist and clinician haematologist in the Ballarat community for many years. George has worked at the Dana Faber Cancer Institute in Boston and as a Research Fellow at Harvard University, and he headed the Cancer Research Unit at the Royal Children’s Hospital in Melbourne.

Professor Stuart Berzins
BSc (Hons) PhD GCUT
Stuart has previously conducted research at Monash University, the Harvard Medical School and University of Melbourne. He now leads a research group at the Institute, investigating human immune responses to cancer. He collaborates with national and international research groups and is working with Professor George Kannourakis and other researchers at the Fiona Elsey Cancer Research Institute and Federation University to establish a regional hub of biomedical research. His research group studies specialised cells and molecules that regulate immune responses against cancer. Higher research goals are to determine if there are defects in immune regulation that contribute to different forms of cancer, and to identify immune cells and molecules that could become targets for new immune-based therapies.

Professor Nuzhat Ahmed
BSc Hons (DU), MSc (KUL), PhD (ANU)
Nuzhat joined the Institute in April 2015 and is the John Turner Professorial Cancer Research Fellow. She holds an adjunct professorial position with the Federation University, Ballarat which strengthens links between the Institute and the University. Professor Ahmed is an experienced cell and molecular biologist and brings a wealth of experience to Institute, particularly in cancer biology. She has a long-standing interest in understanding the molecular mechanisms of ovarian cancer spread. She did her postdoctoral research training in Malaghan Institute of Medical Research, New Zealand, University of Newcastle, Australia, Kanagawa Cancer Centre, Japan and BC Cancer Agency, University of British Columbia in Canada. From 2002-2014 Nuzhat led the Cancer Metastasis Group in Women’s Cancer Research Centre, Royal Women’s Hospital, Melbourne. Her significant contribution has been in establishing novel interactions of cell adhesion molecules with the signalling pathways in cancer, identifying early-stage biomarkers for ovarian cancer screening and understanding the mechanisms of chemoresistance in ovarian cancer patients. These studies have led to several international patents, competitive international and national grants and publications (>70) in reputable cancer journals. Nuzhat has a long-standing interest in understanding the immune cell irregularities in ovarian cancer patients.

1 in 3 women will contract a form of cancer before the age of 85.
Collaborative partnerships and networks

Our research team is well positioned with world class facilities, and a tissue bank of over 3000 patient samples. This facilitates our team to maintain an extensive program of local and international collaborations with other research centres:

**Collaborations**

<table>
<thead>
<tr>
<th></th>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><strong>Professor Jan-Inge Henter</strong></td>
<td>Karolinska Institute, Stockholm (LCH project)</td>
</tr>
<tr>
<td>2</td>
<td><strong>Professor Peter Moore</strong></td>
<td>University of California (LCH project)</td>
</tr>
<tr>
<td>3</td>
<td><strong>Professor Paul Jubinsky</strong></td>
<td>Albert Einstein College of Medicine, New York (chemo-sensitivity testing)</td>
</tr>
<tr>
<td>4</td>
<td><strong>Dr Marty Campbell</strong></td>
<td>Royal Children's Hospital, Melbourne (LCH project)</td>
</tr>
<tr>
<td>5</td>
<td><strong>Professor Dale Godfrey</strong></td>
<td>Doherty Institute (LCH project)</td>
</tr>
<tr>
<td>6</td>
<td><strong>Dr Daniel Pellicci</strong></td>
<td>Doherty Institute</td>
</tr>
<tr>
<td>7</td>
<td><strong>Professor Damian Purcell</strong></td>
<td>Doherty Institute (Murine HCV project)</td>
</tr>
<tr>
<td>8</td>
<td><strong>Dr Daniel Gray</strong></td>
<td>T cells and microenvironment</td>
</tr>
<tr>
<td>9</td>
<td><strong>Prof Rob Ramsay</strong></td>
<td>Peter MacCallum Cancer Institute (CRC project)</td>
</tr>
<tr>
<td>10</td>
<td><strong>Dr Laura Mackay</strong></td>
<td>Peter Doherty Institute (Broad immunology project)</td>
</tr>
<tr>
<td>11</td>
<td><strong>Dr Stephen Daley</strong></td>
<td>Monash University (Broad Immunology project)</td>
</tr>
<tr>
<td>12</td>
<td><strong>Dr Stuart Mannering</strong></td>
<td>St Vincent's Medical Research Institute</td>
</tr>
<tr>
<td>13</td>
<td><strong>Associate Professor Tom Jobling</strong></td>
<td>Monash Medical Centre and Epworth Hospital (Ovarian cancer project)</td>
</tr>
<tr>
<td>14</td>
<td><strong>Dr David Greening</strong></td>
<td>LiMS, Latrobe University (Ovarian Cancer Project)</td>
</tr>
<tr>
<td>15</td>
<td><strong>Dr Jock Findlay</strong></td>
<td>Hudson Institute of Medical Research (Ovarian Cancer Project)</td>
</tr>
<tr>
<td>16</td>
<td><strong>Dr Nick Williamson</strong></td>
<td>Bio 21 Institute (Ovarian and CLL Projects)</td>
</tr>
<tr>
<td>17</td>
<td><strong>Dr Nheim Tran</strong></td>
<td>RMIT (Ovarian Cancer Project)</td>
</tr>
<tr>
<td>18</td>
<td><strong>Dr Rodney Luwor</strong></td>
<td>University of Melbourne (Ovarian Cancer Project)</td>
</tr>
<tr>
<td>19</td>
<td><strong>Dr Christopher Burns</strong></td>
<td>Walter and Eliza Hall Institute (Ovarian Cancer Project)</td>
</tr>
</tbody>
</table>

**Australia**
- Royal Children's Hospital
- Doherty Institute
- Peter MacCallum Cancer Institute
- Monash University
- St Vincent's Medical Research Institute
- Epworth Hospital
- Latrobe University
- Hudson Institute of Medical Research
- Bio 21 Institute
- RMIT
- University of Melbourne
- Walter and Eliza Hall Institute

**North America**
- University of California
- Albert Einstein College of Medicine, New York

**Sweden**
- Karolinska Institute, Stockholm
Publications

Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma

Experimental and Human Evidence for Lipocalin-2 (Neutrophil Gelatinase-Associated Lipocalin [NGAL]) in the Development of Cardiac Hypertrophy and heart failure

Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage

Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells

Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer

Use of Suppression Subtractive Hybridization for Viral Diagnostics

Evaluation of response from axitinib per response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma


Resolution of norfloxacin-induced acute liver failure after N-acetylcysteine therapy: further support for the use of NAC in drug-induced ALF?

Collaboration of Epithelial Mesenchymal Transition and Cancer Stem Cells: Sinister Routes for Chemoresistant Recurrent Ovarian Cancer

For a complete list and to view the research, please visit www.fecri.org.au
Governance

Board of directors

Chair of the Board
Emeritus Professor Wayne Robinson
BVSc, MVSc, PhD, MACVSc, DACVP, DVSc (Hon causa)
Board member since: 2004

Deputy Chair of the Board
David Fisken
BAgSc, MBA
Board member since: 2004

Honorary Director
George Kannourakis
MBBS, B(Med)Sci, PhD, FRACP
Board member since: 2004

Treasurer
Rob Glass
BEc DipAgSci FCA
Board member since: 2005

Company Secretary
Robert Tommasini
LLB, GAICD
Board member since: 2017

Board member
Lisa Hayden
BAppSci (Speech Path)
Board member since: 2013

Board member
Kerryn Shade
AFAIM, FLGP, PSM
Board member since: 2014

Board member
Professor Leigh Sullivan
BSc Agr (Hons) PhD, CPSS MAICD
Board member since: 2016

Board member
Craig Lightfoot
Dip App Sc. Grad Dip App Sc. DMU (Cardiac). GAICD
Board member since: 2017

Board member
Graeme Dixon
BBus
Board member since: 2013

Board member
Georgia Yanner
BA, LLB
Board member since: 2017

Scientific Advisory Committee

The Institute maintains a Scientific Advisory Committee panel to provide guidance and advice to the Institute Director on our research projects. This ensures our projects are externally scrutinised and conceptually endorsed to be of legitimate grounding.

The panel meets biannually and consists of the following recognised experts:

- **Professor Damien Purcell** – University of Melbourne
- **Professor Richard Boyd** – Adjunct Professor (Chief Scientific Officer, Cartherics), Monash University, Hudson Institute.
- **Professor Leigh Sullivan** – Deputy Vice Chancellor, Federation University
- **Dr Daniel Pellicci** – Doherty Institute, Melbourne
Every 11 hours one woman dies of ovarian cancer in Australia. Approximately 1400 Australian women are diagnosed with the cancer each year, and nearly 800 die annually, making ovarian cancer the fourth most common cause of cancer-related death in women in Australia.
Financial commentary

After a very challenging year financially for the year ended 30th June 2016, the 2017 financial year has proven to be a year in which the financial position of the Institute has improved significantly.

The Institute was fortunate to receive bequests totalling $1,963,590 and a further $1,293,339 in donations, $1,000,000 of which was donated by John Turner to set up the John Turner Cancer Research Fund. Direct fundraising raised a further $192,129 and this year we were able to attract $85,947 in grants to support the work of the Institute. Corporate contributions of $81,518 along with interest income of $10,061 help generate total income of $3,622,851 for the year.

After spending $755,353 on laboratory wages and expenses, $84,841 in providing the facilities, $51,247 on general administrative expenses, $181,985 on our development office and incurring depreciation charges of $59,500, the Institute recorded a profit before tax of $2,489,916.

As a result of this profit, the financial position of the Institute has improved markedly, but it should be borne in mind that bequests totalling $1,959,858 made up a good portion of this profit and it is unlikely that the Institute will be in receipt of bequests of this magnitude again in the foreseeable future. Also, the donation received from John Turner was given in the expectation that this money would be spent in the next 12 months in expanding the research activities of Institute and steps have been implemented to achieve this goal. To maintain its ongoing research program, the Institute will continue to rely on significant community support.

For further information and details on the Institute, please visit the website of the independent national regulator of charities, the Australian Charities and Not-for-profits Commission (ACNC) or use the following link:

www.acnc.gov.au/RN52B75Q?ID=C5089532-3F19-4477-BA87-5EEDE94A46B9&noleft=1

Financial Operations for the year ended 30 June 2017

Income 2017
- 54% Bequests
- 36% Donations
- 5% Fundraising
- 2% Corporate contributions
- 3% Grants

Expenditure 2017
- 16% Development office
- 7% Facility & Property
- 5% General administration
- 67% Laboratory
- 5% Depreciation

Consolidated Statement of Financial Position as at 30 June 2017

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current Assets</td>
<td>$3,144,043</td>
<td>$576,162</td>
</tr>
<tr>
<td>Non-Current Assets</td>
<td>$581,661</td>
<td>$589,117</td>
</tr>
<tr>
<td>TOTAL ASSETS</td>
<td>$3,725,704</td>
<td>$1,165,279</td>
</tr>
<tr>
<td>Current Liabilities</td>
<td>$336,386</td>
<td>$271,011</td>
</tr>
<tr>
<td>Non-Current Liabilities</td>
<td>$46,328</td>
<td>$39,595</td>
</tr>
<tr>
<td>TOTAL LIABILITIES</td>
<td>$382,714</td>
<td>$310,606</td>
</tr>
<tr>
<td>Net Assets</td>
<td>$3,342,990</td>
<td>$854,673</td>
</tr>
<tr>
<td>Equity</td>
<td>$2,862,578</td>
<td>$374,261</td>
</tr>
<tr>
<td>TOTAL EQUITY</td>
<td>$3,342,990</td>
<td>$854,673</td>
</tr>
</tbody>
</table>

This statement is an extract from the audited financial statements of the Fiona Elsey Cancer Research Institute for the year ended 30 June 2017 lodged with the Australian Charities and Not-for-profits Commission (ACNC) and are available for viewing on the website of the Commission.
In May we announced the establishment of the John Turner Cancer Research Fund at the Fiona Elsey Cancer Research Institute following a significant 1-million-dollar donation by businessman and philanthropist, John Turner.
If we can reduce cancer deaths in the next forty years by 20% we could save the tax payer: $184 billion

* Source: Cancer in Australia 2017 report, Australian Institute of Health and Welfare
The Institute continues to strive to maintain and develop a strong connection with the community. As a community funded research Institute, this is vital to our longevity.

Our doors are open to all interested members of the community to tour the facility.
Donor Contributions

We gratefully acknowledge the generosity of the following donors:

$1 million +
- John Turner
- Estate of Leslie Kennedy

$100,000 +
- BJT Legal
- Millie and Jack Borbidge
- City of Ballarat
- DNA Ball Lake Bolac
- Dorevitch Pathology
- Estate of Christine Joy Hawksworth
- Estate of Gloria Jean Hadfield
- Estate of Harry & Peggy Maddocks
- Estate of Isobel Jean Tom
- Estate of Ivy May Dunstan
- Estate of Joyce McGregor
- Estate of Joyce Winifred Golden
- Estate of Mary Fletcher Johnston
- Estate of Patricia White
- Estate of Peggy Sinclair McCoy
- Estate of Robert Edgar Clemence
- Fulton Hogan
- NL Gribble
- Stuart & Suzanne Gull
- JG King Homes
- June Wilson Trust
- George & Trudi Kannourakis
- Percy Baxter Charitable Trust
- Jim & Val Selkirk
- Slater & Gordon Asbestos Research
- Southern Cross Aus Stereo
- St John of God Hospital
- Titeline
- Troon Family
- Women’s Golf Ballarat & District
- Bill & Sue Wood
- Crowe Horwath Ballarat (Part of Findex)
- Gaunt Family Foundation

$50,000 +
- Arthur J Gallagher
- Ballarat Community Enterprises
- Ballarat Courier Foundation
- Bendigo Bank
- Andrew & Murray Byrne & Family
- Cancer in Children & Adults
- Dansick Family & Friends
- Estate of Alice Jaques Jende
- Estate of Anne Maree Rodoni
- Estate of Barbara Dorothy Williams
- Estate of Gladys May Brown
- Estate of Isabel Judith King
- Estate of Janet LeMarshall
- Estate of John Green
- Federation University Australia
- Shirley Harvey
- In Memory of Dawn Shade
- Marion Popplewell Charitable Trust
- Melbourne Community Foundation
- Regent Multiplex
- Bruce & Julie Stafford
- Titeline Drilling
- Gekko Systems
- In Memory of Kevin Morrow
- Walsh Quarries Pty Ltd
- Dennis Family Homes

1 in 2 men will contract a form of cancer before the age of 85.
$10,000 +

<table>
<thead>
<tr>
<th>Donor Name</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atmosphere Events</td>
<td>$10,000 +</td>
</tr>
<tr>
<td>Australian Mud Company</td>
<td></td>
</tr>
<tr>
<td>Ballarat &amp; District Trotting Club Inc</td>
<td></td>
</tr>
<tr>
<td>Ballarat Courier</td>
<td></td>
</tr>
<tr>
<td>Ballarat/Sebastopol Cycling Club</td>
<td></td>
</tr>
<tr>
<td>John &amp; Glanda Blay</td>
<td></td>
</tr>
<tr>
<td>Blenkiron Electrical</td>
<td></td>
</tr>
<tr>
<td>Bob Borbidge</td>
<td></td>
</tr>
<tr>
<td>C E Bartlett</td>
<td></td>
</tr>
<tr>
<td>Carpet Gallery Ballarat</td>
<td></td>
</tr>
<tr>
<td>Chip for Charity</td>
<td></td>
</tr>
<tr>
<td>Claytons Ballarat</td>
<td></td>
</tr>
<tr>
<td>Claytons Melbourne</td>
<td></td>
</tr>
<tr>
<td>Cycle Scape</td>
<td></td>
</tr>
<tr>
<td>Dentistry Ballarat</td>
<td></td>
</tr>
<tr>
<td>Graham Dixon</td>
<td></td>
</tr>
<tr>
<td>Dolls Cleaning</td>
<td></td>
</tr>
<tr>
<td>Pam &amp; Grant Douglas</td>
<td></td>
</tr>
<tr>
<td>Bruce &amp; Vicki Edward</td>
<td></td>
</tr>
<tr>
<td>Estate of Arthur Francis Saunders</td>
<td></td>
</tr>
<tr>
<td>Estate of Alfred T. Saunders</td>
<td></td>
</tr>
<tr>
<td>Estate of Arthur Senior c/-Murray Byrne</td>
<td></td>
</tr>
<tr>
<td>Estate of Beryl Doreen Davis</td>
<td></td>
</tr>
<tr>
<td>Estate of Desmond R Oates</td>
<td></td>
</tr>
<tr>
<td>Estate of Father John Martin</td>
<td></td>
</tr>
<tr>
<td>Estate of Gerald Casey</td>
<td></td>
</tr>
<tr>
<td>Eureka Concrete</td>
<td></td>
</tr>
<tr>
<td>Federation of Veteran, Vintage and Classic Vehicle Club</td>
<td></td>
</tr>
<tr>
<td>Freemasons Victoria</td>
<td></td>
</tr>
<tr>
<td>Gems &amp; Jewels</td>
<td></td>
</tr>
<tr>
<td>GMHBA Limited</td>
<td></td>
</tr>
<tr>
<td>Hair Today, Bare Tomorrow</td>
<td></td>
</tr>
<tr>
<td>Hardcore Diamond Products</td>
<td></td>
</tr>
<tr>
<td>Heritage Garden Party</td>
<td></td>
</tr>
<tr>
<td>Hettich</td>
<td></td>
</tr>
<tr>
<td>Lin Huddleston Charitable Fund</td>
<td></td>
</tr>
<tr>
<td>Kevin Joy Architects</td>
<td></td>
</tr>
<tr>
<td>Labrador Indulgence Day</td>
<td></td>
</tr>
<tr>
<td>Lake Imaging</td>
<td></td>
</tr>
<tr>
<td>Lake Learmonth &amp; District Ball Committee</td>
<td></td>
</tr>
<tr>
<td>Laminex Industries</td>
<td></td>
</tr>
<tr>
<td>Lawrie Family Trust</td>
<td></td>
</tr>
<tr>
<td>Mininera Ball Committee</td>
<td></td>
</tr>
<tr>
<td>National Australian Bank</td>
<td></td>
</tr>
<tr>
<td>O &amp; S Holdings P/L</td>
<td></td>
</tr>
<tr>
<td>Ray Oates</td>
<td></td>
</tr>
<tr>
<td>Andrew Oliver</td>
<td></td>
</tr>
<tr>
<td>Pipecon</td>
<td></td>
</tr>
<tr>
<td>Bill &amp; Michelle Ricciardi</td>
<td></td>
</tr>
<tr>
<td>Rivers</td>
<td></td>
</tr>
<tr>
<td>John &amp; Mary Ross</td>
<td></td>
</tr>
<tr>
<td>Rotary Club of Ballarat South</td>
<td></td>
</tr>
<tr>
<td>Ryans IGA</td>
<td></td>
</tr>
<tr>
<td>Pam &amp; Grant Smith</td>
<td></td>
</tr>
<tr>
<td>Nathalie Stevens</td>
<td></td>
</tr>
<tr>
<td>Tanya Daniels - The Good Guys</td>
<td></td>
</tr>
<tr>
<td>Telstra Countrywide</td>
<td></td>
</tr>
<tr>
<td>The Canny Family</td>
<td></td>
</tr>
<tr>
<td>The Show Stoppers Concert</td>
<td></td>
</tr>
<tr>
<td>Kathleen &amp; Joseph Tuddenham Trust</td>
<td></td>
</tr>
<tr>
<td>Vaughan Construction</td>
<td></td>
</tr>
<tr>
<td>Jean Vergeer</td>
<td></td>
</tr>
<tr>
<td>W H Sarah Pty Ltd</td>
<td></td>
</tr>
<tr>
<td>Hillary Willow Smith</td>
<td></td>
</tr>
<tr>
<td>1000 lap swimmers (in memory of Rachel Block)</td>
<td></td>
</tr>
<tr>
<td>3BA/Power FM</td>
<td></td>
</tr>
<tr>
<td>Eclipse Ford</td>
<td></td>
</tr>
<tr>
<td>Petstock</td>
<td></td>
</tr>
<tr>
<td>Smartpix</td>
<td></td>
</tr>
<tr>
<td>MP Williamson</td>
<td></td>
</tr>
<tr>
<td>Lake Wendouree Luxury Apartments</td>
<td></td>
</tr>
<tr>
<td>Barry &amp; Louis James &amp; Family</td>
<td></td>
</tr>
<tr>
<td>Jenman Group</td>
<td></td>
</tr>
<tr>
<td>Protect</td>
<td></td>
</tr>
<tr>
<td>John Wade</td>
<td></td>
</tr>
<tr>
<td>Hayden Real Estate</td>
<td></td>
</tr>
<tr>
<td>Bert Wilson Will Trust</td>
<td></td>
</tr>
<tr>
<td>Estate of Aubrey William Wye</td>
<td></td>
</tr>
<tr>
<td>Beechworth Bakery</td>
<td></td>
</tr>
</tbody>
</table>
Corporate partners

Affiliated Institute

Federation University Australia
Many supporters and organisations continue to attend events and host functions in our name. These wonderful events raise much needed funds, whilst also raising awareness of our work.

Jeremy & Iesha Hummer’s Tasmanian Bike Ride- January 2017
Morrow Motors Horsham Test Drive Day- January 2017
Chip for Charity Golf Day -February 2017
Port Fairy Music Festival, Volunteer event- March 2017
Uniting Church Wendouree Morning tea- May 2017
Black Tie Gala- May 2017
Vintage & Classic Car Club Ballarat Morning tea- May 2017
Mercedes Benz Ballarat Christmas in July- July 2017
Dry July for Dennis Foley- July 2017
Kirsty Wakefield cut her hair- July 2017
Josh Lee “Adios dreadlocks”- July 2017
Movie event, All for One- August 2017
Ballarat Golf Club Ladies “Pink Day”- September 2017
Salvation Army “Girls Night In” - October 2017
Ballarat Lifestyle Magazine Melbourne Cup event- November 2017
Pomonal Progress Association raffle- November 2017
Springfest- November 2017
Fashion for Funeral- November 2017
Harrier Jump Jet display- November 2017
Movie event, Bad Mums 2- November 2017
Dansick Family Annual Shopping Tour -November 2017
Federation Uni Children’s Picnic- December 2017
Navarre Ladies Christian Group event- December 2017
In 2018, it is estimated that 138,321 new cases of cancer will be diagnosed in Australia. 74,644 males and 63,676 females.*
2017 Ballarat Cycle Classic

The event saw a variety of road and mountain bike events, as well as an outdoor cinema. Significant media attention for the Institute was also generated by a strong radio, television and print media.

A magnificent total of over $150,000.00 was raised because of the 2017 Ballarat Cycle Classic. This annual event celebrated its tenth year having raised more than $1.5 million for the Institute since its inception in 2008. The event saw more than 1500 cyclists and walkers take part in wintry conditions. A true testament to the support that the Institute has from the community. Due to the strong support of local businesses, 100% of all entry fees were directed to cancer research.

Thank you to the following sponsors:

Platinum

Gold
City of Ballarat
Fulton Hogan
Arthur J Gallagher

Silver
Lake Imaging
Goves Cycles
National Australia Bank
Dennis Family Homes
JG King Homes

Bronze
Natures Cargo
Lake Wendouree Luxury Apartments
Eureka Concrete
Atmosphere Events
Central Highlands Water

Media Partners
Channel 9 Ballarat
The Courier
PowerFM and 3BA

* Source: Cancer in Australia 2017 report, Australian Institute of Health and Welfare